Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-1-60327-829-4_15
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The 315–316 deletion determines the BXP-21 antibody epitope but has no effect on the function of wild type ABCG2 or the Q141K variant

  2009cited by this paper
• Pharmacogenetic Pathway Analysis of Docetaxel Elimination

  2009cited by this paper
• Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

  2009cited by this paper
• Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.

  2008cited by this paper
• Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements

  2008cited by this paper
• Lessons learned from development of docetaxel

  2008cited by this paper
• Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?

  2008cited by this paper
• Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia

  2008cited by this paper
• A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer

  2008cited by this paper
• Pharmacogenetics of membrane transporters: a review of current approaches.

  2008cited by this paper
• Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

  2008cited by this paper
• ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

  2008cited by this paper
• Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer

  2008cited by this paper
• PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients

  2008cited by this paper
• An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.

  2007cited by this paper
• Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4α, and Constitutive Androstane Receptor with Docetaxel Pharmacokinetics

  2007cited by this paper
• Influence of ketoconazole on the fecal and urinary disposition of docetaxel

  2007cited by this paper
• A Phase I Dose Escalation Study of Weekly Docetaxel and Carboplatin in Elderly Patients With Nonsmall Cell Lung Cancer

  2007cited by this paper
• Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition.

  2007cited by this paper
• Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.

  2007cited by this paper
• Mitoxantrone permeability in MDCKII cells is influenced by active influx transport.

  2007cited by this paper
• Re‐evaluation and functional classification of non‐synonymous single nucleotide polymorphisms of the human ATP‐binding cassette transporter ABCG2

  2007cited by this paper
• Preclinical antitumor activity of the oral platinum analog satraplatin

  2007cited by this paper
• Pre‐clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen‐independent prostate cancer

  2007cited by this paper
• Broadening the clinical use of platinum drug–based chemotherapy with new analogues

  2007cited by this paper
• Differential Subcellular Distribution of Mitoxantrone in Relation to Chemosensitization in Two Human Breast Cancer Cell Lines

  2007cited by this paper
• Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect

  2007cited by this paper
• Inhibition of catechol-O-methyltransferase increases estrogen-DNA adduct formation.

  2007cited by this paper
• Clinical pharmacodynamic factors in docetaxel toxicity

  2007cited by this paper
• A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871

  2007cited by this paper
• Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters

  2006cited by this paper
• Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis

  2006cited by this paper
• Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients

  2006cited by this paper
• Synergistic antitumor activity of the combination of satraplatin (S) and docetaxel (D) in H460 human non-small cell lung carcinoma (NSCLC) xenografted in nude mice

  2006cited by this paper
• Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux

  2006cited by this paper
• Potential biomarker for early risk assessment of prostate cancer

  2006cited by this paper
• Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel

  2006cited by this paper
• Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin

  2006cited by this paper
• Phase II Evaluation of Docetaxel Plus Exisulind in Patients With Androgen Independent Prostate Carcinoma

  2006cited by this paper
• Role of ABCG2 as a biomarker for predicting resistance to CPT‐11/SN‐38 in lung cancer

  2006cited by this paper
• Population Pharmacokinetic-Pharmacodynamic Model for Neutropenia with Patient Subgroup Identification: Comparison across Anticancer Drugs

  2006cited by this paper
• Pharmacokinetic analysis of docetaxel during haemodialysis in a patient with locally advanced non-small cell lung cancer.

  2006cited by this paper
• Clinical Pharmacokinetics of Docetaxel

  2006cited by this paper
• Determination of unbound docetaxel and paclitaxel in plasma by ultrafiltration and liquid chromatography-tandem mass spectrometry.

  2006cited by this paper
• Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.

  2006cited by this paper
• Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms

  2006cited by this paper
• Significance of the Minor Cytochrome P450 3A Isoforms

  2006cited by this paper
• Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention

  2006cited by this paper
• The Val158Met polymorphism of the catechol-O-methyltransferase gene is associated with the PSA-progression-free survival in prostate cancer patients treated with estramustine phosphate.

  2005cited by this paper
• Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells.

  2005cited by this paper
• Effect of androgen-ablation and hormonal cycling on docetaxel (D) clearance in patients with metastatic prostate cancer (MPC)

  2005cited by this paper
• Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.

  2005cited by this paper
• MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid

  2005cited by this paper
• Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel

  2005cited by this paper
• Breast cancer resistance protein: Molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics

  2005cited by this paper
• Single nucleotide polymorphisms modify the transporter activity of ABCG2

  2005cited by this paper
• EXPRESSION AND FUNCTION OF ABCB1 AND ABCG2 IN HUMAN PLACENTAL TISSUE

  2005cited by this paper
• Single‐nucleotide polymorphisms in the 17β‐hydroxysteroid dehydrogenase genes might predict the risk of side‐effects of estramustine phosphate sodium in prostate cancer patients

  2005cited by this paper
• Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics of protein‐unbound docetaxel in cancer patients

  2005cited by this paper
• FUNCTIONAL ASSESSMENT OF ABCG2 (BCRP) GENE POLYMORPHISMS TO PROTEIN EXPRESSION IN HUMAN PLACENTA

  2005cited by this paper
• Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale.

  2004cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

  2004cited by this paper
• Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias

  2004cited by this paper
• Clinical and pharmacokinetic study of docetaxel in elderly non-small-cell lung cancer patients

  2004cited by this paper
• Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype

  2004cited by this paper
• Functional Analysis of SNPs Variants of BCRP/ABCG2

  2004cited by this paper
• The Induction of Cytochrome P450 3A5 (CYP3A5) in the Human Liver and Intestine Is Mediated by the Xenobiotic Sensors Pregnane X Receptor (PXR) and Constitutively Activated Receptor (CAR)*

  2004cited by this paper
• Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

  2004cited by this paper
• Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue.

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Docetaxel serum protein binding with high affinity to alpha1-acid glycoprotein

  2004cited by this paper
• P‐glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells

  2004cited by this paper
• A distinct "side population" of cells with high drug efflux capacity in human tumor cells.

  2004cited by this paper
• Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2

  2004cited by this paper
• Estrogens and anti‐estrogens: Key mediators of prostate carcinogenesis and new therapeutic candidates

  2004cited by this paper
• The MDR1 (ABCB1) Gene Polymorphism and its Clinical Implications

  2004cited by this paper
• Clinical pharmacokinetics of unbound docetaxel: Role of polysorbate 80 and serum proteins

  2003cited by this paper
• A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma.

  2003cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• The mechanism of action of docetaxel (Taxotere®) in xenograft models is not limited to bcl-2 phosphorylation

  2003cited by this paper
• Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma.

  2003cited by this paper
• Cisplatin and platinum drugs at the molecular level. (Review).

  2003cited by this paper
• Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel.

  2003cited by this paper
• Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

  2002cited by this paper
• Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme.

  2002cited by this paper
• Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.

  2002cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2).

  2002cited by this paper
• Chiral discrimination in platinum anticancer drugs.

  2002cited by this paper
• C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.

  2002cited by this paper
• Rapid biotransformation of satraplatin by human red blood cells in vitro

  2002cited by this paper
• Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

  2002cited by this paper
• Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer.

  2002cited by this paper
• 2.4-Å Crystal Structure of the Asymmetric Platinum Complex {Pt(ammine)(cyclohexylamine)}2+ Bound to a Dodecamer DNA Duplex*

  2002cited by this paper
• Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer.

  2001cited by this paper
• Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids.

  2001cited by this paper
• Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.

  2001cited by this paper
• Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel

  2001cited by this paper

• No citing papers are available for this paper.